Mount Sinai study also shows imaging for early detection and monitoring can improve prediction and prevention of premature death
Tag: Mount Sinai Heart
SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe and Effective for Treating Patients Who Have Suffered a Heart Attack
The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.
Intravascular Imaging Significantly Improves Survival, Safety, and Outcomes in Cardiovascular Stenting Procedures Over Conventional Angiography
Results from this large-scale synthesis of all prior clinical trials could increase usage of several types of high-resolution imaging for guiding interventional coronary procedures
Mount Sinai Renames Top-Ranked Heart Hospital to Honor Valentin Fuster, MD, PhD, and His Legacy of Excellence
“Mount Sinai Fuster Heart Hospital” furthers vision of world-leading cardiac care and research that prevents heart disease worldwide
Mount Sinai Announces Partnership With the Chiba Institute of Technology in Japan Focusing on Artificial Intelligence to Transform Cardiovascular Research
Agreement aims to help make clinical trials more efficient and lead to faster advances in patient care
Preschoolers From Low-Income Families May Have Worse Health and Benefit Less From Health Promotion Interventions Than Children With Higher Socioeconomic Status
Mount Sinai study focused on Harlem preschools emphasizes the need for specialized health promotion programs in classrooms starting at an early age
Mount Sinai Announces Partnership With the Brazilian Clinical Research Institute to Advance Cardiovascular Disease Research and Medical Education
Agreement aims to improve patient care and outcomes on a global scale
Optical Coherence Tomography May Improve Safety and Outcomes for Stenting Procedures in Heart Disease Patients Compared to Conventional Angiography
Results from a large-scale clinical trial results could increase usage of high resolution imaging for guiding interventional coronary procedures
Mount Sinai Receives Significant Funding to Study Which Coronary Revascularization Procedure Best Improves Survival and Quality of Life for Women and Underserved Minority Groups
The Icahn School of Medicine at Mount Sinai will help lead and launch the first clinical trial focusing on women and minority populations to determine which coronary revascularization procedure best improves their survival and quality of life.
George Dangas, MD, PhD, Named President of Society for Cardiovascular Angiography & Interventions
First Mount Sinai cardiologist to hold this prestigious position
Coronary Bioresorbable Scaffolds Nearly as Safe and Effective as Conventional Metal Stents for Heart Disease Patients
First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI).
A Novel Mechanism May Be Effective in Patients With Severe Hypertriglyceridemia and Prior Episodes of Acute Pancreatitis
A novel type of therapy, known as ANGPTL3 inhibitor therapy, was effective in lowering triglycerides in certain types of patients with severe hypertriglyceridemia (sHTG) who had a prior episode(s) of acute pancreatitis. sHTG is a well-established risk factor for recurrent episodes of acute pancreatitis. These high-risk patients were the focus of a phase 2 study that was led by the Icahn School of Medicine at Mount Sinai and sponsored and funded by Regeneron.
High-Dose Anticoagulation Can Reduce Intubations and Improve Survival for Hospitalized COVID-19 Patients
High-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation.
Transcatheter Mitral Valve Repair in Heart Failure Patients Significantly Reduces Hospitalizations and Improves Survival
Breakthrough findings from study led by Mount Sinai researcher could improve outcomes for high-risk patients
Learn CPR and Lower Your Stress: Mount Sinai Cardiologists Emphasize Their Importance During American Heart Month
Doctors warn about lack of knowledge of administering CPR, especially in high-risk groups, and the rise of stress-related heart issues
Valentin Fuster, MD, PhD, Receives Prestigious Award from City of Barcelona, Spain
Mount Sinai Heart President given top honor for his extraordinary scientific achievements
Samin Sharma, MD, Named Director of the Mount Sinai Cardiovascular Clinical Institute
Mount Sinai Heart expands leadership
Deepak L. Bhatt, MD, MPH, Named Director of Mount Sinai Heart
Will also serve as the first-ever Dr. Valentin Fuster Professor of Cardiovascular Medicine
Valentin Fuster, MD, PhD, Named President of Mount Sinai Heart
Mount Sinai Health System’s globally acclaimed cardiologist Valentin Fuster, MD, PhD, has been named President of Mount Sinai Heart, a newly created position, effective Sunday, January 1, 2023. Dr. Fuster will continue in his roles as Physician-in-Chief of The Mount Sinai Hospital and as the Richard Gorlin, MD/Heart Research Foundation Professor at the Icahn School of Medicine at Mount Sinai.
A Consistent Lack of Sleep Negatively Impacts Immune Stem Cells, Increasing Risk of Inflammatory Disorders and Heart Disease
Mount Sinai study also shows catching up on sleep doesn’t reverse possible negative effects on cellular level
Valentin Fuster, MD, PhD, Receives Prestigious Award from Cardiovascular Research Foundation
Mount Sinai Heart leader will be recognized for his exceptional career achievements at the 34th annual conference.
New Risk Score Predicts Mortality for Atrial Fibrillation Patients Undergoing Transcatheter Aortic Valve Replacement
Mount Sinai researchers develop new risk stratification tool to optimize patient care and outcomes after TAVR
“Polypill” Reduces Cardiovascular Mortality by 33 Percent in Patients Treated After a Heart Attack
A three-drug medication known as a “polypill,” developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population.
High Blood Viscosity Can Predict Higher Risk of Death in Hospitalized COVID-19 Patients
EMBARGOED UNTIL JULY 18, 2022, 2PM EST Study Title: “Association of Blood Viscosity with Mortality among Patients Hospitalized with COVID-19” Journal: Journal of the American College of Cardiology – *Embargoed until July…
Blacks Found Twice as Likely to Have Atherosclerosis as Hispanics in Young Adult Populations in Underserved Communities
A unique Mount Sinai study focused on a multi-ethnic, underserved community in New York City shows that young Black adults are twice as likely to have atherosclerosis as similarly situated young Hispanic adults.
Stress Testing Can Help Determine Which Patients Are Likely to Benefit From Heart Procedures to Improve Survival
Mount Sinai study can help guide proper treatment course for patients depending on heart function and severity of heart damage
Specific Environmental Exposures may Help Predict Increased Risk of Death from Cardiovascular Disease
A new study from the Icahn School of Medicine at Mount Sinai quantifies the cardiovascular risk posed by exposure to specific environmental factors, showing, for example, that air pollution heightens the risk of heart disease mortality by 17 percent.
Heart Failure Patients Unvaccinated Against COVID-19 Are Three Times More Likely to Die From It Than Boosted Heart Failure Patients
EMBARGOED UNTIL JUNE 9, 2022, 10AM EST (New York, NY – June 9, 2022) – Heart failure patients who are unvaccinated against SARS-CoV-2, the virus that causes COVID-19, are three times more likely to die if infected with the virus…
Mount Sinai Cardiologist Develops New Risk Score to Help Predict Possible Contrast-Associated Kidney Injury After Percutaneous Coronary Intervention
Assessment can help stratify high-risk patients for monitoring before, during, and after procedures to improve outcomes
Novel Surgical Device Can Potentially Improve Outcomes of Coronary Bypass Grafting That Uses Leg Veins
(New York, NY – November 13, 2021) –A novel device called venous external support (VEST) may lead to increased longevity and durability of saphenous (leg) vein grafting during coronary artery bypass surgery, according to a new trial done in collaboration…
New Treatment Approach for Advanced Coronary Artery Disease Leads to Improved Outcomes
Study outlines better way to identify where stents are necessary
Shrinking Waveforms on Electrocardiograms Predict Worsening Health and Death of Hospitalized COVID-19 and Influenza Patients
Spotting changes in the heart’s electrical activity may prompt more-aggressive treatment and monitoring.
Mount Sinai Cardiologist Leads Effort to Outline Guidance for Management of Heart Failure Patients During COVID-19 Pandemic
New scientific statement aims to establish more streamlined care to improve outcomes in this high-risk group
Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement
Mount Sinai study is first to compare this anticoagulant with the standard of care in large randomized clinical trial
Mount Sinai Heart Earns Two Prestigious Recognitions for Heart Failure and Catherization Lab
Awards highlight highest level of quality of care
Mount Sinai Recruits Internationally Recognized Cardiovascular Immunology Researcher
Filip Swirski, PhD, named Director of Mount Sinai’s new Cardiovascular Research Institute
Ali N. Zaidi, MD, to Receive Prestigious Honor From American Heart Association on Long Island
Cardiologist will partner with organization to create awareness for congenital heart disease to improve community health
Two Mount Sinai Leaders Receive Prestigious Honors from American Heart Association in New York City
Two of Mount Sinai’s top doctors will be honored with prestigious awards at the American Heart Association’s New York City Heart and Stroke Ball, taking place virtually on Wednesday, June 9.
Fat Around the Heart Linked to Increased Risk of Heart Failure
EMBARGOED UNTIL MAY 24 2:00PM EST (New York, NY – May 24, 2021) – Having excess pericardial fat—fat around the heart—increases the risk of developing heart failure, especially in women, according to new Mount Sinai research. Women with high amounts…
Mount Sinai Cardiovascular Doctors to Receive Honors During American College of Cardiology 70th Annual Scientific Session
William Whang, MD, Associate Professor of Medicine (Cardiology), and Gilbert Tang, MD, MSc, MBA, Associate Professor of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai, are receiving the 2021 Simon Dack Awards for their exceptional contributions to the Journal of the American College of Cardiology (JACC).
Study Shows Significant Reduction in Triglycerides in Patients at High Risk for Acute Pancreatitis Through Novel Monoclonal Antibody
The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancreatitis in a phase 2 global study led by Mount Sinai
Heart Disease and COVID-19: Focusing on Exercise, Mental Health, and Nutrition are Critical for High-Risk Groups
February is American Heart Month and cardiologists from the Mount Sinai Health System are sharing tips on heart disease prevention to lower the risk of heart attack, stroke, and COVID-19.
Mount Sinai Cardiologist Awarded $2.9 Million NIH Grant to Advance Work with Stem Cells and Heart Repair after Heart Attack
Research may lead to identifying novel therapies for cardiac patients
Mount Sinai Heart Awarded Transcatheter Valve Certification by American College of Cardiology
Only program in New York City to receive prestigious recognition
A Novel Monoclonal Antibody Therapy Cuts LDL Cholesterol by Half in a High-Risk Patient Population, Study Shows
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called “bad” cholesterol—by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found.
Mount Sinai’s Valentin Fuster, MD, PhD, Honored by Thai Royal Family for Outstanding Medical Contributions
Thailand’s Royal Family has named Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, a winner of the 29th annual Prince Mahidol Award in the field of Medicine.
Heart Failure Patients With COVID-19 Nearly Twice as Likely to Die and at Triple the Risk of Intubation Compared to Those Without Pre-Existing Heart Condition
Results may lead to closer monitoring of heart failure patients in hospital and at home
Ultrasounds Show Impact of COVID-19 on the Heart
International study may guide therapeutic strategies in patients with and without underlying heart conditions
Mount Sinai’s Cardiac Catheterization Labs Given Highest Safety Ratings in New York State
Mount Sinai cardiologist also ranked No. 1 for safety in percutaneous coronary interventions
Mount Sinai Health System Hospitals Receive Top Quality Achievement Awards for Stroke and Cardiac Care
Mount Sinai Health System Hospitals Receive Top Quality Achievement Awards for Stroke and Cardiac Care